FOLFOX Chemotherapy Regimens: Comprehensive Explanation
The FOLFOX family consists of several variants that differ primarily in oxaliplatin dosing, leucovorin formulation, and 5-FU administration schedules, with mFOLFOX-6 now established as the preferred regimen for both adjuvant and metastatic colorectal cancer treatment. 1, 2, 1
1. Cancer Indications by Regimen
FOLFOX-4
- Stage III colon cancer (adjuvant): Category 1 recommendation based on MOSAIC trial 1, 3
- Metastatic colorectal cancer (first-line): Demonstrated superiority over 5-FU/LV alone 4
- Clinical setting: Historically used but largely replaced by mFOLFOX-6 in current practice 1
mFOLFOX-6 (Modified FOLFOX-6)
- Stage III colon cancer (adjuvant): Preferred FOLFOX regimen, Category 1 1, 5
- High-risk Stage II colon cancer (adjuvant): Reasonable option for patients with poor prognostic features 1, 5
- Metastatic colorectal cancer: Standard first-line therapy 5, 6, 7
- Clinical setting: Control arm for all recent NCI adjuvant studies; preferred over FOLFOX-4 1
FOLFOX-6
- Metastatic colorectal cancer (second-line): After failure of first-line therapy 8
- Clinical setting: Less commonly used variant, primarily in Japanese studies 8
FOLFOX-7
- Metastatic colorectal cancer: Investigated in dose-dense strategies with intermittent oxaliplatin 9, 10
- Clinical setting: Not standard; used in specific protocols exploring oxaliplatin-free intervals to reduce neuropathy 10
2. Drug Doses by Regimen
FOLFOX-4 2, 3, 4
- Oxaliplatin: 85 mg/m² IV over 2 hours, Day 1
- Leucovorin: 200 mg/m² IV over 2 hours, Days 1 and 2
- 5-FU bolus: 400 mg/m² IV bolus, Days 1 and 2
- 5-FU infusion: 600 mg/m² IV over 22 hours, Days 1 and 2
- Cycle: Every 14 days
mFOLFOX-6 2, 5, 1, 5, 4
- Oxaliplatin: 85 mg/m² IV over 2 hours, Day 1
- Leucovorin: 400 mg/m² IV over 2 hours, Day 1 (or levo-leucovorin 200 mg/m²)
- 5-FU bolus: 400 mg/m² IV bolus, Day 1
- 5-FU infusion: 2,400 mg/m² continuous IV over 46-48 hours (1,200 mg/m²/day × 2 days)
- Cycle: Every 14 days
FOLFOX-6 8
- Oxaliplatin: 100 mg/m² IV over 2 hours, Day 1
- L-Leucovorin: 200 mg/m² IV over 2 hours, Day 1
- 5-FU bolus: 400 mg/m² IV bolus, Day 1
- 5-FU infusion: 2,400 mg/m² continuous IV over 46 hours
- Cycle: Every 14 days
FOLFOX-7 9, 10
- Oxaliplatin: 130 mg/m² IV over 2 hours, Day 1
- Levo-leucovorin: 200 mg/m² IV over 2 hours, Day 1
- 5-FU infusion: 2,400 mg/m² continuous IV over 46-48 hours (NO bolus)
- Cycle: Every 14 days
3. Administration Schedule Details
mFOLFOX-6 (Standard Protocol) 2, 5, 1, 4
Sequence:
- Oxaliplatin 85 mg/m² and leucovorin 400 mg/m² administered concurrently via Y-connector over 2 hours, Day 1
- Immediately followed by 5-FU 400 mg/m² IV bolus
- Then 5-FU 1,200 mg/m²/day continuous infusion over 46-48 hours (total 2,400 mg/m²)
Treatment Duration:
- Adjuvant setting: 12 cycles (6 months total) 11, 5, 4
- Metastatic setting: Continue until disease progression or unacceptable toxicity 4
Important Safety Note: Orders should specify 24-hour units (1,200 mg/m²/day) rather than total dose over 48 hours to minimize medication errors 2, 1
FOLFOX-4 Administration 2, 3
Day 1:
- Oxaliplatin 85 mg/m² IV over 2 hours
- Leucovorin 200 mg/m² IV over 2 hours (can be concurrent with oxaliplatin)
- 5-FU 400 mg/m² IV bolus
- 5-FU 600 mg/m² continuous infusion over 22 hours
Day 2:
- Leucovorin 200 mg/m² IV over 2 hours
- 5-FU 400 mg/m² IV bolus
- 5-FU 600 mg/m² continuous infusion over 22 hours
Cycle interval: Every 14 days
FOLFOX-7 Administration 9, 10
Key difference: Eliminates 5-FU bolus entirely
- Oxaliplatin 130 mg/m² and levo-leucovorin 200 mg/m² over 2 hours, Day 1
- 5-FU 2,400 mg/m² continuous infusion over 46-48 hours only
- Cycle every 14 days
4. Key Differences Between Regimens
FOLFOX-4 vs. mFOLFOX-6
| Feature | FOLFOX-4 | mFOLFOX-6 |
|---|---|---|
| Hospital visits | Twice weekly (Days 1 and 2) | Once every 2 weeks |
| Oxaliplatin dose | 85 mg/m² | 85 mg/m² |
| 5-FU bolus | 400 mg/m² × 2 days (800 mg/m² total) | 400 mg/m² × 1 day |
| 5-FU infusion | 600 mg/m² × 22h × 2 days (1,200 mg/m² total) | 2,400 mg/m² over 46-48h |
| Total 5-FU per cycle | 2,000 mg/m² | 2,800 mg/m² |
| Leucovorin | 200 mg/m² × 2 days | 400 mg/m² × 1 day |
| Convenience | Less convenient | More convenient [1,8] |
| Current use | Largely replaced | Preferred standard [1] |
FOLFOX-6 vs. mFOLFOX-6
| Feature | FOLFOX-6 | mFOLFOX-6 |
|---|---|---|
| Oxaliplatin dose | 100 mg/m² | 85 mg/m² |
| 5-FU bolus | 400 mg/m² | 400 mg/m² |
| 5-FU infusion | 2,400 mg/m² | 2,400 mg/m² |
| Leucovorin form | L-leucovorin 200 mg/m² | Leucovorin 400 mg/m² or levo-leucovorin 200 mg/m² |
| Geographic use | Primarily Japan [8] | Worldwide standard |
FOLFOX-7 vs. mFOLFOX-6
| Feature | FOLFOX-7 | mFOLFOX-6 |
|---|---|---|
| Oxaliplatin dose | 130 mg/m² (higher) | 85 mg/m² |
| 5-FU bolus | None | 400 mg/m² |
| 5-FU infusion | 2,400 mg/m² | 2,400 mg/m² |
| Rationale | Dose-dense oxaliplatin with planned breaks [10] | Continuous standard dosing |
| Neuropathy strategy | Intermittent administration (6 cycles on, 12 off, then reintroduce) [10] | Continuous until toxicity |
| Standard use | Investigational only [9,10] | Standard of care |
5. Modified FOLFOX-6 Variants
Standard mFOLFOX-6 with Bevacizumab 5, 6
- Add bevacizumab 5 mg/kg IV Day 1 every 2 weeks (metastatic setting)
- All other doses remain identical
Duration-Modified mFOLFOX-6 (IDEA Study) 11, 5
For adjuvant treatment:
- Low-risk Stage III (T1-3N1): Consider 3 months (6 cycles) of CAPEOX preferred over 3 months mFOLFOX-6
- High-risk Stage III (T4 or N2): 6 months (12 cycles) remains standard
- Rationale: Reduces cumulative neuropathy without compromising efficacy in selected patients 11
6. Common Pitfalls and Caveats
Leucovorin Formulation 1, 2, 1
- Leucovorin 400 mg/m² = Levo-leucovorin 200 mg/m² (equipotent doses)
- During leucovorin shortages, lower doses (20-200 mg/m²) show similar efficacy 1
- Treatment without leucovorin is reasonable if unavailable, with 10% 5-FU dose increase if tolerated 1
Neuropathy Management 1, 3, 7
- Grade 3 peripheral sensory neuropathy occurs in 12-17% with FOLFOX 1, 3
- Persists in 15% at 4 years (mostly grade 1) 1
- Avoid ice application to extremities during oxaliplatin infusion 4
- Calcium/magnesium infusions are not recommended for neuropathy prevention 7
Age Considerations 12, 5
- Benefits of oxaliplatin-containing regimens are more limited in patients ≥70 years 5
- No evidence that adding oxaliplatin benefits patients aged ≥70 in adjuvant setting 5
- Consider fluoropyrimidine monotherapy in elderly patients 7
Dosing Error Prevention 2, 1
- Always order 5-FU as 1,200 mg/m²/day × 2 days, NOT as 2,400 mg/m² over 46-48 hours
- This prevents potentially fatal overdosing errors 2, 1
Regimens NOT Recommended 1, 5
- FLOX (bolus 5-FU/LV/oxaliplatin): Higher diarrhea rates, not preferred 1, 3
- Bevacizumab, cetuximab, panitumumab, irinotecan: Should NOT be used in adjuvant setting outside clinical trials 1, 5
7. Treatment Timing
Adjuvant Therapy 5
- Initiate within 3 weeks postoperatively when medically able
- Must start no later than 2 months after surgery
- Delays beyond 8 weeks result in 14% decrease in overall survival 1